Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Ibritumomab tiuxetan
Trade Name Zevalin
Synonyms IDEC Y2B8
Drug Descriptions

Zevalin (britumomab tiuxetan) is Yttrium-90 combined with the anti-CD20 antibody, rituximab, which may deliver radiation to tumor cells (PMID: 27497027). Zevalin (britumomab tiuxetan) is FDA approved for use in patients with low-grade or follicular B-cell non-Hodgkin's lymphoma (FDA.gov).

DrugClasses CD20 Antibody 17
CAS Registry Number 206181-63-7
NCIT ID C29981


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Ibritumomab tiuxetan Rituximab anti-thymocyte globulin 0 1
Ibritumomab tiuxetan Ibritumomab tiuxetan 0 1
Ibritumomab tiuxetan + Rituximab Ibritumomab tiuxetan Rituximab 0 1

Additional content available in CKB BOOST